Researchers want to prevent alpha-synuclein from accumulating in the brain. To do so, the team searched for drugs that turn down alpha-synuclein production. They then tested the drugs in mice and stem cells and studied in data from the health records of millions of people living in Norway. The results of their efforts, point to a new drug development path for PD.
IBM’s Watson beat real-life contestants on Jeopardy. Now researchers are hoping this icon of artificial intelligence will help people with cancer win as well by providing a rapid, comprehensive report of the genetic mutations at the root of their specific disease and the therapies that target them.
A stem cell-based method can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a more localized way, report investigators.
CRISPR, the gene-editing technology that has taken biology by storm, is now more powerful than ever. Scientists have assembled a library of RNA sequences that can be used by researchers to direct the CRISPR-cas9 complex to cut DNA with exquisite, unprecedented precision.
A preclinical report demonstrates that entinostat, Syndax’s oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (programmed death receptor-1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).